Of note, serum antibodies against aquaporin 4 (AQP4) are a strong diagnostic biomarker that allows for distinguishing MS from NMO: anti-AQP4 antibodies are found in 70–80% of NMO patients but not in MS patients [12,15]. Here, AQP4 is linked to myeloid sarcoma.